Krmar Rafael T, Berg Ulla B
Karolinska Institutet, Department for Clinical Science, Intervention and Technology, Division of Pediatrics, Karolinska University Hospital, Huddinge, Sweden.
Am J Hypertens. 2008 Oct;21(10):1093-9. doi: 10.1038/ajh.2008.251. Epub 2008 Aug 14.
Hypertension in pediatric renal transplants is a widespread condition associated with high mortality risk in early adult life. Ambulatory blood pressure monitoring (ABPM) was found to be superior to office blood pressure (BP) in identifying true hypertensive and responders to treatment. The aim of this study was to investigate the role of repeated ABPM, performed at yearly intervals following transplantation, in the assessment and decision-making processes of post-transplant hypertension.
Thirty-seven recipients (23 males; aged 10.5 +/- 4.3 years) who were followed for 4.3 +/- 2.2 years (range 2-9) after transplantation were eligible for analysis. The mean follow-up time between the baseline (1 year post-transplantation) and the most recent ABPM examination was 3.3 +/- 2.2 years (range 1-8).
Throughout the follow-up period, antihypertensive therapy was either started or intensified in 27 recipients. These interventions were decided based on ABPM results obtained on 40 of 44 occasions. At last follow-up, 24 of 29 treated hypertensive recipients displayed controlled BP. This figure was significantly higher compared to our historical hypertensive control recipients in whom ABPM was applied for the first time in treatment at 6 +/- 3.3 years (range 2-15) after transplantation, while therapeutic decisions were driven by office BP measurements (95 % confidence interval (95% CI) for the difference between proportions (80.6-32 %) 36-60 %, P = 0.001).
Our study shows that, in a population with high risk for hypertension, repeated ABPM may significantly help to improve BP control.
小儿肾移植受者的高血压是一种普遍存在的疾病,与成年早期的高死亡风险相关。动态血压监测(ABPM)在识别真正的高血压患者和治疗反应者方面优于诊室血压测量。本研究的目的是探讨移植后每年进行一次的重复ABPM在移植后高血压评估和决策过程中的作用。
37名接受者(23名男性;年龄10.5±4.3岁)在移植后随访4.3±2.2年(范围2 - 9年),符合分析条件。基线(移植后1年)至最近一次ABPM检查的平均随访时间为3.3±2.2年(范围1 - 8年)。
在整个随访期间,27名接受者开始或强化了抗高血压治疗。这些干预措施是根据44次中的40次ABPM结果决定的。在最后一次随访时,29名接受治疗的高血压受者中有24名血压得到控制。与我们历史上首次在移植后6±3.3年(范围2 - 15年)进行ABPM治疗的高血压对照受者相比,这一数字显著更高,当时治疗决策由诊室血压测量驱动(比例差异的95%置信区间(95%CI)(80.6 - 32%)36 - 60%,P = 0.001)。
我们的研究表明,在高血压高风险人群中,重复ABPM可能显著有助于改善血压控制。